Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy

Brain

Volumn 136, Issue 2, 2013, Pages

  Klopstock, T ^a   Metz, G ^b   Yu Wai Man, P ^c,d   Buchner B ^a   Gallenmuller C ^a   Bailie, M ^c,d   Nwali, N ^c,d   Griffiths, P G ^c,d   Von Livonius, B ^e   Reznicek, L ^e   Rouleau, J ^f   Coppard, N ^b   Meier, T ^b   Chinnery, P F ^c,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Santhera Pharmaceuticals   (Switzerland)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF MUNICH   (Germany)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IDEBENONE; MITOCHONDRIAL DNA; PLACEBO;

CONTRAST SENSITIVITY; GENE MUTATION; HUMAN; INTENTION TO TREAT ANALYSIS; LEBER HEREDITARY OPTIC NEUROPATHY; LETTER; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84874322602     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws279     Document Type: Letter

References (11)

1. Barnils N, Mesa E, Munoz S, Ferrer-Artola A, Arruga J. Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy. Arch Soc Esp Oftalmol 2007; 82: 377-80.
2. Carelli V, Barboni P, Zacchini A, Mancini R, Monari L, Cevoli S, et al. Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient. J Neurol Sci 1998; 160: 183-8.
3. Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011; 134: e188.
4. Carelli V, Valentino ML, Liguori R, Meletti S, Vetrugno R, Provini F, et al. Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases. J Neurol Neurosurg Psychiatry 2001; 71: 813-6.
5. Cortelli P, Montagna P, Pierangeli G, Lodi R, Barboni P, Liguori R, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997; 148: 25-31.
6. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011; 6: e17963.
7. Howell N. Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. Vision Res 1998; 38: 1495-504.
8. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134: 2677-86.
9. Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet 1992; 340: 368-9.
10. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 2000; 20: 166-70.
11. Sabet-Peyman EJ, Khaderi KR, Sadun AA. Is leber hereditary optic neuropathy treatable? Encouraging results with idebenone in both prospective and retrospective trials and an illustrative case. J Neuroophthalmol 2012; 32: 54-7.